R&D Insight tracks and evaluates drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch. This is an open access article published under the terms of the Creative Commons License "Attribution-NonCommercial-NoDerivative...
RVX-208 is the first-in-class BD2-selective inhibitor of BET bromodomain tested in Phase II clinical trials for treatment of coronary syndromes and atherosclerosis. How to Use: In vitro: RVX-208 was used at 10 µM final concentration in various in vitro assays. In vivo: RVX-208 was ...
Persistent latent reservoir in resting CD4+ T cells is a major obstacle in curing HIV-1 infection. Effective strategies for eradication of the HIV-1 reservoir are urgently needed. We report here for the first time that two BET inhibitors, RVX-208, which has entered phase II clinical trials f...
RVX-208 is a recently reported inhibitor of bromo and extraterminal (BET) family proteins (including BRD2-4 and BRDT) with selectivity for the second bromodomain (BD2), currently in phase III clinical trials. Despite of its promising antitumor activity, due to the conserved folds of the first...
Data from phase 1a and 1b/2a human trials showed RVX-208 to be...doi:10.1016/S0735-1097(10)61542-2Wong, Norman C.Gordon, AllanJohansson, JanWagner, GregoryChiacchia, Fabrizio S.McLure, KevinJahagirdar, RaviElsevier BVJournal of the American College of Cardiology...
RVX-208 is a recently reported inhibitor of bromo and extraterminal (BET) family proteins (including BRD2-4 and BRDT) with selectivity for the second bromodomain (BD2), currently in phase III clinical trials. Despite of its promising antitumor activity, due to the conserved folds of the first...
W49 RVX-208 GIVEN ORALLY RAISES PLASMA apoA-I AND HDL IN HUMAN CLINICAL TRIALS - Atherosclerosis Supplementsdoi:10.1016/S1567-5688(10)70050-7A. GordonJ. JohanssonG. WagnerF. ChiacchiaN. WongElsevier Ireland LtdAtherosclerosis Supplements
The ongoing phase 3 post-ACS clinical trial in T2DM patients, BETonMACE, is investigating the effect of apabetalone on MACE reduction and will report in 2019.Laura M TsujikawaBrooke RakaiShovon DasChristopher HallidayStephanie C StotzMichael Sweeney...
W49 RVX-208 GIVEN ORALLY RAISES PLASMA apoA-I AND HDL IN HUMAN CLINICAL TRIALSdoi:10.1016/s1567-5688(10)70050-7A. GordonJ. JohanssonG. WagnerF. ChiacchiaN. WongElsevierAtherosclerosis Supplements
Conclusion Administration of the BET protein inhibitor RVX-208 showed no greater increase in apoA-I or HDL-C or incremental regression of atherosclerosis than administration of placebo. Trial Registration ClinicalTrials.gov identifier—NCT01067820.American Journal of Cardiovascular Drugs...